BioCentury | Aug 27, 2019
Clinical News

DMD data to inform Santhera's choice under vamorolone option deal

...Santhera and ReveraGen revealed Tuesday that glucocorticoid vamorolone showed improvement in timed function tests, the primary...
...the time to run/walk 10 meters and the six-minute walk test vs. the lowest dose. ReveraGen BioPharma Inc....
...making Idorsia Ltd. (SIX:IDIA) its majority shareholder. Idorsia inherited the option to license vamorolone from ReveraGen...
BioCentury | Nov 30, 2018
Company News

Deal with Idorsia gives Santhera shot at second DMD candidate

...company's investment in the pivotal Phase IIb VISION-DMD (VBP15-004) trial being conducted by DMD company ReveraGen BioPharma Inc....
...the latter's acquisition by Johnson & Johnson (NYSE:JNJ), inheriting Actelion's option to license vamorolone from ReveraGen...
...opt in for exclusive worldwide rights in exchange for a $20 million payment to ReveraGen. ReveraGen...
BioCentury | Nov 21, 2018
Company News

Deal with Idorsia gives Santhera shot at second DMD candidate

...company's investment in the pivotal Phase IIb VISION-DMD (VBP15-004) trial being conducted by DMD company ReveraGen BioPharma Inc....
...the latter's acquisition by Johnson & Johnson (NYSE:JNJ), inheriting Actelion's option to license vamorolone from ReveraGen...
...opt in for exclusive worldwide rights in exchange for a $20 million payment to ReveraGen. ReveraGen...
BioCentury | Feb 4, 2017
Strategy

Actelion, take two

...an option to obtain exclusive, worldwide rights to vamorolone from ReveraGen BioPharma Inc. under a November deal. ReveraGen...
...year. (A) J&J has an option to ACT-132577; details are not disclosed; (B) In-licensed from ReveraGen BioPharma Inc....
...Switzerland AstraZeneca plc (LSE:AZN; NYSE: AZN), London, U.K. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. ReveraGen BioPharma Inc....
BioCentury | Nov 17, 2016
Company News

ReveraGen, Actelion deal

...Actelion and ReveraGen partnered to develop and commercialize vamorolone to treat Duchenne muscular dystrophy (DMD). Actelion...
...than prior to data from a planned Phase IIb trial. If Actelion exercises the option, ReveraGen...
...testing for DMD. ReveraGen BioPharma Inc. , Rockville, Md. Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland Business: Musculoskeletal Nora Weintraub Actelion Ltd. ReveraGen BioPharma Inc. Nuclear...
BioCentury | Sep 30, 2013
Clinical News

ReveraGen preclinical data

...leucocytes to levels resembling that of wild-type mice. Data were published in EMBO Molecular Medicine. ReveraGen...
...reached for next steps for the dissociative glucocorticoid and inhibitor of NF-kappa B (NF-kB) . ReveraGen BioPharma Inc....
BioCentury | Dec 15, 2011
Strategy

TRND take two

...projects Afraxis Inc. Not applicable p21 protein (Cdc42 Rac)-activated kinase (PAK) inhibitor Fragile X syndrome ReveraGen Biopharma Inc....
BioCentury | Oct 13, 2011
Strategy

TRNDing toward translation

...to be an encumbrance to companies." The third and fourth partnerships include a project from ReveraGen BioPharma Inc....
...of a subgroup of patients with acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). ReveraGen...
...Human Genome Research Institute , Bethesda, Md. NIH Center for Translational Therapeutics , Bethesda, Md. ReveraGen BioPharma Inc....
BioCentury | Oct 3, 2011
Company News

Afraxis, ReveraGen, Viamet pharmaceuticals news

...and expects to open a third round this fall. Afraxis Inc. , La Jolla, Calif. ReveraGen Biopharma Inc....
...and laboratory resources, including funding. Business: Pharmaceuticals The projects are: VBP15, a dissociative glucocorticoid from ReveraGen...
BioCentury | Sep 30, 2011
Company News

NIH rare disease program selects projects

...projects with R&D staff and laboratory resources, including funding. The projects are: a compound from ReveraGen Biopharma Inc....
Items per page:
1 - 10 of 10
BioCentury | Aug 27, 2019
Clinical News

DMD data to inform Santhera's choice under vamorolone option deal

...Santhera and ReveraGen revealed Tuesday that glucocorticoid vamorolone showed improvement in timed function tests, the primary...
...the time to run/walk 10 meters and the six-minute walk test vs. the lowest dose. ReveraGen BioPharma Inc....
...making Idorsia Ltd. (SIX:IDIA) its majority shareholder. Idorsia inherited the option to license vamorolone from ReveraGen...
BioCentury | Nov 30, 2018
Company News

Deal with Idorsia gives Santhera shot at second DMD candidate

...company's investment in the pivotal Phase IIb VISION-DMD (VBP15-004) trial being conducted by DMD company ReveraGen BioPharma Inc....
...the latter's acquisition by Johnson & Johnson (NYSE:JNJ), inheriting Actelion's option to license vamorolone from ReveraGen...
...opt in for exclusive worldwide rights in exchange for a $20 million payment to ReveraGen. ReveraGen...
BioCentury | Nov 21, 2018
Company News

Deal with Idorsia gives Santhera shot at second DMD candidate

...company's investment in the pivotal Phase IIb VISION-DMD (VBP15-004) trial being conducted by DMD company ReveraGen BioPharma Inc....
...the latter's acquisition by Johnson & Johnson (NYSE:JNJ), inheriting Actelion's option to license vamorolone from ReveraGen...
...opt in for exclusive worldwide rights in exchange for a $20 million payment to ReveraGen. ReveraGen...
BioCentury | Feb 4, 2017
Strategy

Actelion, take two

...an option to obtain exclusive, worldwide rights to vamorolone from ReveraGen BioPharma Inc. under a November deal. ReveraGen...
...year. (A) J&J has an option to ACT-132577; details are not disclosed; (B) In-licensed from ReveraGen BioPharma Inc....
...Switzerland AstraZeneca plc (LSE:AZN; NYSE: AZN), London, U.K. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. ReveraGen BioPharma Inc....
BioCentury | Nov 17, 2016
Company News

ReveraGen, Actelion deal

...Actelion and ReveraGen partnered to develop and commercialize vamorolone to treat Duchenne muscular dystrophy (DMD). Actelion...
...than prior to data from a planned Phase IIb trial. If Actelion exercises the option, ReveraGen...
...testing for DMD. ReveraGen BioPharma Inc. , Rockville, Md. Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland Business: Musculoskeletal Nora Weintraub Actelion Ltd. ReveraGen BioPharma Inc. Nuclear...
BioCentury | Sep 30, 2013
Clinical News

ReveraGen preclinical data

...leucocytes to levels resembling that of wild-type mice. Data were published in EMBO Molecular Medicine. ReveraGen...
...reached for next steps for the dissociative glucocorticoid and inhibitor of NF-kappa B (NF-kB) . ReveraGen BioPharma Inc....
BioCentury | Dec 15, 2011
Strategy

TRND take two

...projects Afraxis Inc. Not applicable p21 protein (Cdc42 Rac)-activated kinase (PAK) inhibitor Fragile X syndrome ReveraGen Biopharma Inc....
BioCentury | Oct 13, 2011
Strategy

TRNDing toward translation

...to be an encumbrance to companies." The third and fourth partnerships include a project from ReveraGen BioPharma Inc....
...of a subgroup of patients with acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). ReveraGen...
...Human Genome Research Institute , Bethesda, Md. NIH Center for Translational Therapeutics , Bethesda, Md. ReveraGen BioPharma Inc....
BioCentury | Oct 3, 2011
Company News

Afraxis, ReveraGen, Viamet pharmaceuticals news

...and expects to open a third round this fall. Afraxis Inc. , La Jolla, Calif. ReveraGen Biopharma Inc....
...and laboratory resources, including funding. Business: Pharmaceuticals The projects are: VBP15, a dissociative glucocorticoid from ReveraGen...
BioCentury | Sep 30, 2011
Company News

NIH rare disease program selects projects

...projects with R&D staff and laboratory resources, including funding. The projects are: a compound from ReveraGen Biopharma Inc....
Items per page:
1 - 10 of 10